CAS: 2393-23-9; 4-Methoxybenzylamine

上下游产品

CAS号874-90-8 4-甲氧基苯甲腈 | CAS号123-11-5 4-甲氧基苯甲醛; 对甲氧基苯... | CAS号70978-37-9 1-(叠氮甲基)-4-甲氧基苯 | CAS号3717-21-3 Benzaldehyde,4-... | CAS号171414-16-7 N-(4-甲氧基苄基)-2-硝基苯磺酰胺 | CAS号3424-93-9 4-甲氧基苯甲酰胺 | CAS号58837-16-4 1,3,5-tris[(4-m... | CAS号105-13-5 对甲氧基苄醇 | CAS号112129-06-3 N-chloro-1-(4-m... | CAS号3694-57-3 4-甲氧基苄基异硫氰酸酯 | CAS号491-36-1 4-Quinazolinone | CAS号122022-10-0 (+/-)-2,3-dihyd... | CAS号3526-43-0 N-苯基-4-甲氧基苄胺 | CAS号54879-64-0 N-[(4-甲氧基苯基)甲基]... | CAS号104-15-4 对甲苯磺酸 | CAS号108-95-2 苯酚 | CAS号79246-03-0 N-(4-methoxyben... | CAS号98-11-3 苯磺酸

4-甲氧基苯甲醛置于盐酸,三乙基硅烷,七氧化二铼,水体系中,用 二氯甲烷 用作溶剂,化学反应 6.5H,反应生成4-甲氧基苄胺
参考文献:The Direct Reductive Amination Of Electron-Deficient Amines With Aldehydes: The Unique Reactivity Of The Re2O7 Catalyst
标题:The Direct Reductive Amination Of Electron-Deficient Amines With Aldehydes: The Unique Reactivity Of The Re2O7 Catalyst
摘要:首次实现了采用re2O7催化剂和硅烷作为氢源,对cbz-,Boc-,Etoco-,Fmoc-,Bz-,Arso2-,Ar2Po-等电子不足的胺类保护基胺与醛的直接还原胺化反应.观测到优异的区域选择性单烃基化和化学选择性还原胺化.
Doi:10.1039/c2Cc33185C

专利信息

专利号:WO-2021260722-A1
优先权日:2020-06-21
标 题:Design, synthesis of novel oxyindole inhibitors of denv rna dependent rna polymerase
发明人：GUNDLA RAMBABU; ASTHANA SHAILENDRA; BHATTACHARYYA SANKAR; MADDIPATI VENKATANARAYANA CHOWDARY; MITTAL LOVIKA; KAUR JASKARAN; RAWAT YOGITA
权利人:TRANSLATIONAL HEALTH SCIENCE AND TECH INSTITUTE; GANDHI INSTITUTE OF TECH AND MANAGEMENT
摘要:The present invention is drawn to novel compounds of formula I, II and III, including any conformational isomeric form, salts and solvates for inhibition of DENV RNA dependent and RNA polymerase. The present invention also discloses a process of synthesis of the compounds, compositions comprising the said compounds and use of the compounds and treatment comprising the compounds of the present invention.

专利号:US-7183417-B2
优先权日:2004-04-09
标题:Simple stereocontrolled synthesis of salinosporamide A
发明人：COREY ELIAS J
权利人:HARVARD COLLEGE
摘要:A simple and effective stereocontrolled synthesis of salinosporamide A(1) n nhas been developed which follows the pathway outlined in the FIGURE. The process, the first total synthesis of salinosporamide A, is capable of providing the compound in substantial quantities for further biological studies. In addition to the method of Scheme I, the present invention also includes several novel synthetic intermediate compounds, several intermediate steps of the preferred synthetic process; and the uses of these compounds in the preparation of synthetic derivatives of the compound Salinosporamide A. Salinosporamide A is of special interest as a synthetic target because of its protein in vitro cytotoxic activity against many tumor cell lines (IC 50 values of 10 nM or less).

专利号:US-8853220-B1
优先权日:2011-02-25
标题 :Synthesis of 2,6,9-tri-substituted-4,8-dinitro-2,6,9-triazabicyclo[3.3.1]nona-3,7-diene intermediates toward the preparation of polyaza-adamantanes
发明人：STERN ALFRED G; DIAMOND CRAIG J
权利人:STERN ALFRED G; DIAMOND CRAIG J; US NAVY
摘要:The present invention relates to methods for synthesizing energetic compounds and intermediates thereof. Specifically, the present invention relates to methods for synthesizing adamantanes and intermediates that are useful in such synthesis. Synthesized intermediates are useful in the synthesis of bicyclic and tricyclic substituted adamantanes. Examples of various intermediates are: acyclic 2-nitromalonaldehyde intermediates, 2,6,9-tri-substituted-4,8-dinitro-2,6,9-triazabicyclo[3.3.1]nona-3,7-dienes and 2,6-dinitro-4,8,9,10-tetra-aza-4,8,9,10-tetra-substituted adamantanes. Intermediates synthesized according to the methods of the present invention are useful toward the synthesis of tetraaza-adamantanes, which can serve as precursors to potentially superior new high-energy-density compounds (HEDCs). The tricyclic intermediate compound has a structure of Formula III: n n n n n n n n n n n n where R is one of a benzyl, 4-methoxybenzyl, acetyl, nitro, formyl, allyl, and a carboethoxyl group.

专利号:US-8895736-B1
优先权日:2011-02-25
标题:Synthesis of substituted 2-nitromalonaldehyde intermediates toward the preparation of polyaza-adamantanes
发明人：STERN ALFRED G; DIAMOND CRAIG J
权利人:STERN ALFRED G; DIAMOND CRAIG J; US NAVY
摘要:The present invention relates to methods for synthesizing energetic compounds and intermediates thereof. Specifically, the present invention relates to methods for synthesizing adamantanes and intermediates that are useful in such synthesis. Synthesized intermediates are useful in the synthesis of bicyclic and tricyclic substituted adamantanes. Examples of various intermediates are: acyclic 2-nitromalonaldehyde intermediates, 2,6,9-tri-substituted-4,8-dinitro-2,6,9-triazabicyclo[3.3.1]nona-3,7-dienes and 2,6-dinitro-4,8,9,10-tetra-aza-4,8,9,10-tetra-substituted adamantanes. Intermediates synthesized according to the methods of the present invention are useful toward the synthesis of tetraaza-adamantanes, which can serve as precursors to potentially superior new high-energy-density compounds (HEDCs).

专利号:US-9296706-B1
优先权日:2011-02-25
标 题:Synthesis of 2,6-dinitro-4,8,9,10-tetraaza-4,8,9,10-tetra-substituted adamantanes
发明人：STERN ALFRED G; DIAMOND CRAIG J
权利人:STERN ALFRED G; DIAMOND CRAIG J; US NAVY
摘要:The present invention relates to methods for synthesizing energetic compounds and intermediates thereof. Specifically, the present invention relates to methods for synthesizing adamantanes and intermediates that are useful in such synthesis. Synthesized intermediates are useful in the synthesis of bicyclic and tricyclic substituted adamantanes. Examples of various intermediates are: acyclic 2-nitromalonaldehyde intermediates, 2,6,9-tri-substituted-4,8-dinitro-2,6,9-triazabicyclo[3.3.1]nona-3,7-dienes and 2,6-dinitro-4,8,9,10-tetra-aza-4,8,9,10-tetra-substituted adamantanes. Intermediates synthesized according to the methods of the present invention are useful toward the synthesis of tetraaza-adamantanes, which can serve as precursors to potentially superior new high-energy-density compounds (HEDCs).

专利号:US-5877278-A
优先权日:1992-09-24
标题:Synthesis of N-substituted oligomers
发明人：ZUCKERMANN RONALD N; GOFF DANE A; NG SIMON; SPEAR KERRY; SCOTT BARBARA O; SIGMUND AARON C; GOLDSMITH RICHARD A; MARLOWE CHARLES K; PEI YAZHONG; RICHTER LUTZ; SIMON REYNA
权利人:CHIRON CORP
摘要:A solid-phase method for the synthesis of N-substituted oligomers, such as poly (N-substituted glycines) (referred to herein as poly NSGs) is used to obtain oligomers, such as poly NSGs of potential therapeutic interest which poly NSGs can have a wide variety of side-chain substituents. Each N-substituted glycine monomer is assembled from two 'sub-monomers' directly on the solid support. Each cycle of monomer addition consists of two steps: (1) acylation of a secondary amine bound to the support with an acylating agent comprising a leaving group capable of nucleophilic displacement by -NH2, such as a haloacetic acid, and (2) introduction of the side-chain by nucleophilic displacement of the leaving group, such as halogen (as a solid support-bound alpha -haloacetamide) with a sufficient amount of a second sub-monomer comprising an -NH2 group, such as a primary amine, alkoxyamine, semicarbazide, acyl hydrazide, carbazate or the like. Repetition of the two step cycle of acylation and displacement gives the desired oligomers. The efficient synthesis of a wide variety of oligomeric NSGs using automated synthesis technology of the present method makes these oligomers attractive candidates for the generation and rapid screening of diverse peptidomimetic libraries. The oligomers of the invention, such as N-substituted glycines (i.e. poly NSGs) disclosed here provide a new class of peptide-like compounds not found in nature, but which are synthetically accessible and have been shown to possess significant biological activity and proteolytic stability. Combinatorial libraries of cyclic compounds are disclosed wherein the cyclic compounds are comprised of at least one ring structure derived from cyclization of a peptoid backbone. The diversity of product compounds is generated by the sequential addition of substituted submonomers. The combinatorial library includes 10 or more, preferably 100 or more, and more preferably 1,000 or more distinct and different compounds. The library includes each of the product compounds in retrievable and analyzable amounts and preferably includes at least one biologically active compound. Methods of synthesizing the combinatorial libraries and assay devices produced using the libraries are disclosed as is methodology for screening for and obtaining biologically active cyclic organic compounds.